We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MDT Stock May Benefit From New Regulatory Wins for Its MiniMed 780G
Read MoreHide Full Article
Key Takeaways
Medtronic gained FDA clearance for SmartGuard algorithm integration with Abbott's Instinct sensor.
Medtronic won FDA approval for MiniMed 780G use in insulin-requiring type 2 diabetes in adults.
MDT's 780G with Meal Detection is the first automated insulin delivery system for this population.
Medtronic plc (MDT - Free Report) recently announced two regulatory milestones for its MiniMed 780G system portfolio. The FDA has cleared the company’s SmartGuard algorithm as an interoperable automated glycemic controller, enabling integration with Abbott’s (ABT - Free Report) Instinct sensor for type 1 diabetes. In addition, the MiniMed 780G system secured approval for use in adults 18 and above, with insulin-requiring type 2 diabetes.
The developments represent a significant advancement in Medtronic’s efforts to expand the proven performance and outcomes of its MiniMed 780G automated insulin delivery (AID) system to more people living with diabetes.
Likely Trend of MDT Stock Following the News
Following the announcement on Sept. 2, MDT shares dipped 1.2%, closing at $92.25 on Wednesday. On a promising note, the Diabetes business is consistently growing above the company average due to the strength of the 780G system and Simpler Sync sensor in international markets. Medtronic has heavily invested in Diabetes over the past few years and is now entering a strong innovation cycle with both new technology and new indications. We expect these latest milestones to support the company’s revenue growth and also help a rebound in the stock’s performance.
Medtronic has a market capitalization of $118.33 billion. The Zacks Consensus Estimate for the company’s fiscal 2026 revenues indicates 6.8% growth over fiscal 2025. It surpassed earnings estimates in each of the trailing four quarters, the average surprise being 2.20%.
More on MDT’s Regulatory Achievements
The Instinct sensor, designed exclusively by Abbott for MiniMed AID and Smart MDI systems, is the world's smallest, thinnest, most discreet integrated CGM and offers a wear time of up to 15 days. The latest clearance, along with the previously cleared MiniMed 780G insulin pump as an alternate controller enabled (ACE) pump, completes the Medtronic FDA pre-market approval pathway for the Instinct sensor integration with the MiniMed 780G system for people living with type 1 diabetes.
Image Source: Zacks Investment Research
In the coming weeks, Medtronic and Abbott plan to complete their necessary compliance documentation to enable sensor integration and marketing. Once complete, the regulatory process will be concluded, after which ordering for the Instinct sensor with the MiniMed 780G system will begin. Existing customers will have priority access through the Innovations Program. Pre-orders for the Simplera Sync sensor are also expected to open later this month.
Meanwhile, the FDA’s approval of the MiniMed 780G system for people with insulin-requiring type 2 diabetes makes it the first and only AID system with Meal Detection technology available to this population. People living with type 2 diabetes who require insulin encounter daily challenges that affect both their physical health and emotional well-being — including frequent injections, meal planning and glucose monitoring. Clinical evidence demonstrates that use of the MiniMed 780G system can improve glycemic outcomes and reduce the treatment burden.
The MiniMed 780G system is currently available for type 2 diabetes with the Guardian 4 sensor and will be available with the Simplera Sync sensor when pre-orders begin later this month. Medtronic also plans to submit 510(k) applications seeking clearance for an interoperable pump indicated for type 2 diabetes, which would enable future integration with the Instinct sensor.
Industry Prospects Favor MDT
According to Precedence Research, the global diabetes device market was valued at $32.74 billion in 2024 and is expected to grow at a compound annual growth rate of 7.7% through 2034.
Some of the main factors driving the market’s growth are the rising prevalence of obesity among the population, growing health consciousness, increasing awareness regarding diabetes, technological advancements in diabetes monitoring devices, easy availability of diabetes devices and high personal disposable income.
Other Developments at MDT
In July, Medtronic secured CE Mark to expand indications of the MiniMed 780G system for use by individuals aged two years and older, during pregnancy, as well as type 2 insulin-requiring diabetes. To gain CE Mark for this expansion of indications, published clinical data in two-to-six-year-olds, pregnant women and people living with type 2 diabetes were reviewed.
MDT Stock Price Performance
In the past year, Medtronic shares have risen 3.9% compared with the industry’s 3.4% growth.
MDT’s Zacks Rank and Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold).
Estimates for Envista’s 2025 earnings per share have increased 7.6% in the past 30 days. Shares of the company have rallied 19.1% in the past year compared with the industry’s 3.2% rise. Its earnings yield of 5.4% also outpaced the industry’s -0.9% yield. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Estimates for Phibro Animal Health’s fiscal 2026 earnings per share have climbed 5 cents to $2.35 in the past 30 days. Shares of the company have surged 100.7% in the past year compared with the industry’s 3.2% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%. In the last reported quarter, it delivered an earnings surprise of 9.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MDT Stock May Benefit From New Regulatory Wins for Its MiniMed 780G
Key Takeaways
Medtronic plc (MDT - Free Report) recently announced two regulatory milestones for its MiniMed 780G system portfolio. The FDA has cleared the company’s SmartGuard algorithm as an interoperable automated glycemic controller, enabling integration with Abbott’s (ABT - Free Report) Instinct sensor for type 1 diabetes. In addition, the MiniMed 780G system secured approval for use in adults 18 and above, with insulin-requiring type 2 diabetes.
The developments represent a significant advancement in Medtronic’s efforts to expand the proven performance and outcomes of its MiniMed 780G automated insulin delivery (AID) system to more people living with diabetes.
Likely Trend of MDT Stock Following the News
Following the announcement on Sept. 2, MDT shares dipped 1.2%, closing at $92.25 on Wednesday. On a promising note, the Diabetes business is consistently growing above the company average due to the strength of the 780G system and Simpler Sync sensor in international markets. Medtronic has heavily invested in Diabetes over the past few years and is now entering a strong innovation cycle with both new technology and new indications. We expect these latest milestones to support the company’s revenue growth and also help a rebound in the stock’s performance.
Medtronic has a market capitalization of $118.33 billion. The Zacks Consensus Estimate for the company’s fiscal 2026 revenues indicates 6.8% growth over fiscal 2025. It surpassed earnings estimates in each of the trailing four quarters, the average surprise being 2.20%.
More on MDT’s Regulatory Achievements
The Instinct sensor, designed exclusively by Abbott for MiniMed AID and Smart MDI systems, is the world's smallest, thinnest, most discreet integrated CGM and offers a wear time of up to 15 days. The latest clearance, along with the previously cleared MiniMed 780G insulin pump as an alternate controller enabled (ACE) pump, completes the Medtronic FDA pre-market approval pathway for the Instinct sensor integration with the MiniMed 780G system for people living with type 1 diabetes.
Image Source: Zacks Investment Research
In the coming weeks, Medtronic and Abbott plan to complete their necessary compliance documentation to enable sensor integration and marketing. Once complete, the regulatory process will be concluded, after which ordering for the Instinct sensor with the MiniMed 780G system will begin. Existing customers will have priority access through the Innovations Program. Pre-orders for the Simplera Sync sensor are also expected to open later this month.
Meanwhile, the FDA’s approval of the MiniMed 780G system for people with insulin-requiring type 2 diabetes makes it the first and only AID system with Meal Detection technology available to this population. People living with type 2 diabetes who require insulin encounter daily challenges that affect both their physical health and emotional well-being — including frequent injections, meal planning and glucose monitoring. Clinical evidence demonstrates that use of the MiniMed 780G system can improve glycemic outcomes and reduce the treatment burden.
The MiniMed 780G system is currently available for type 2 diabetes with the Guardian 4 sensor and will be available with the Simplera Sync sensor when pre-orders begin later this month. Medtronic also plans to submit 510(k) applications seeking clearance for an interoperable pump indicated for type 2 diabetes, which would enable future integration with the Instinct sensor.
Industry Prospects Favor MDT
According to Precedence Research, the global diabetes device market was valued at $32.74 billion in 2024 and is expected to grow at a compound annual growth rate of 7.7% through 2034.
Some of the main factors driving the market’s growth are the rising prevalence of obesity among the population, growing health consciousness, increasing awareness regarding diabetes, technological advancements in diabetes monitoring devices, easy availability of diabetes devices and high personal disposable income.
Other Developments at MDT
In July, Medtronic secured CE Mark to expand indications of the MiniMed 780G system for use by individuals aged two years and older, during pregnancy, as well as type 2 insulin-requiring diabetes. To gain CE Mark for this expansion of indications, published clinical data in two-to-six-year-olds, pregnant women and people living with type 2 diabetes were reviewed.
MDT Stock Price Performance
In the past year, Medtronic shares have risen 3.9% compared with the industry’s 3.4% growth.
MDT’s Zacks Rank and Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Envista (NVST - Free Report) and Phibro Animal Health (PAHC - Free Report) . Both carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for Envista’s 2025 earnings per share have increased 7.6% in the past 30 days. Shares of the company have rallied 19.1% in the past year compared with the industry’s 3.2% rise. Its earnings yield of 5.4% also outpaced the industry’s -0.9% yield. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Estimates for Phibro Animal Health’s fiscal 2026 earnings per share have climbed 5 cents to $2.35 in the past 30 days. Shares of the company have surged 100.7% in the past year compared with the industry’s 3.2% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%. In the last reported quarter, it delivered an earnings surprise of 9.6%.